On Thursday, EnteroMedics Inc (NASDAQ:ETRM)’s shares declined -34.24% to $0.191.
ETRM has market value of $30.86 million while its EPS was booked as $-0.37 in the last 12 months. The stock has 106.40 million shares outstanding while 20.90% shares of the company were owned by institutional investors. Beta value of the company was 2.31; beta is used to measure riskiness of the security.
The mean estimate for the short term price target for EnteroMedics Inc (NASDAQ:ETRM) stands at $2.75 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $7.00 while the lower price target estimate is at $100.
Analysts mean recommendation for the stock is 1.80. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders.
Boston Scientific Corporation (NYSE:BSX)’s shares gained 1.45% to $18.94.
BSX is currently valued at $25.09 billion. The company has 1.35 billion shares outstanding and 91.90% shares of the company were owned by institutional investors. The company has 3.45 value in price to sale ratio while price to book ratio was recorded as 3.97. The company exchanged hands with 9.92 million shares as compared to its average daily volume of 10.46 million shares. It beta stands at 1.04.
The mean estimate for the short term price target for Boston Scientific Corporation (NYSE:BSX) stands at $20.76 according to 23 Analysts. The higher price target estimate for the stock has been calculated at $23.00 while the lower price target estimate is at $19.00.
Analysts mean recommendation for the stock is 1.90. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses.
At the end of Thursday’s trade, Keryx Biopharmaceuticals (NASDAQ:KERX)‘s shares dipped -6.12% to $5.06.
KERX has beta value of 3.59. The company has the market capitalization of $566.99 million. Return on assets ratio of the company was -78.40% while its return on equity ratio was -98.50%. ATR value of company was 0.47 while stock volatility for week was 9.78% while for month was 11.35%. Debt to equity ratio of the company was 0.01 and its current ratio was 4.80.
The mean estimate for the short term price target for Keryx Biopharmaceuticals (NASDAQ:KERX) stands at $10.91 according to 11 Analysts. The higher price target estimate for the stock has been calculated at $19.00 while the lower price target estimate is at $2.50.
Analysts mean recommendation for the stock is 2.60. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.